Panax Notoginseng

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: heart inflammation pain

Research Overview

Research on Panax notoginseng (Sanqi/Tianqi) has focused most heavily on its phytochemistry and cardiovascular/cerebrovascular pharmacology. Multiple reviews report isolation of >200 constituents, with saponins (notoginseng saponins; ginsenosides such as Rg1, Rd, and notoginsenoside R1) emphasized as major bioactive components, alongside flavonoids and cyclopeptides. Comparative work with P. ginseng highlights a compositional skew toward higher saponin content in P. notoginseng, aligning with its traditional indications related to “blood stasis,” hemostasis, swelling, and pain. Mechanistic preclinical studies span anti-inflammatory, anti-atherosclerotic, immunomodulatory, and anti-tumor activities, but the densest experimental literature centers on vascular and ischemia-related models.

The strongest evidence in these studies supports protective effects in ischemic injury contexts, particularly cerebrovascular disease and myocardial infarction, primarily from preclinical models and mechanistic assays. In cerebral ischemia/reperfusion models, plant-derived exosome-like nanoparticles from P. notoginseng reportedly cross the blood–brain barrier without modification, reduce infarct volume, improve behavioral outcomes, preserve BBB integrity, and shift microglia from pro-inflammatory (M1) toward anti-inflammatory (M2) phenotypes, with lipids implicated as key effectors and PI3K/Akt signaling as a candidate pathway. In acute myocardial infarction models, P. notoginseng saponins (PNS) are reported to reduce infarct size and improve cardiac function, with proposed mechanisms including antiplatelet effects (via platelet function assays), enhanced endothelial migration/angiogenesis, and cardiomyocyte autophagy (e.g., AMPK/CaMKII phosphorylation). A separate, well-developed evidence base concerns herb–drug interactions: P. notoginseng and its constituents can alter pharmacodynamics and pharmacokinetics of co-administered drugs through modulation of CYP enzymes and transporters (notably P-glycoprotein), raising particular concern for narrow-therapeutic-index medications while also suggesting potential for synergy and drug-delivery applications (e.g., amphipathic saponins improving solubility/absorption).

Key gaps include translation to rigorous clinical evidence and standardization. The studies emphasize mechanistic and in vivo/in vitro findings, but do not establish comparative effectiveness, optimal dosing, long-term safety, or clinically meaningful endpoints in well-controlled human trials across indications (stroke recovery, post-MI heart failure prevention, bleeding-related uses, etc.). Additional needs include bioactivity-guided isolation to link specific molecules (and non-saponin fractions such as lipids in exosome-like nanoparticles) to defined targets; structure–function relationships among saponins; systems-level “multi-target” network pharmacology validated experimentally; and clearer characterization of variability by plant part (aboveground vs underground), preparation, and quality control. Finally, herb–drug interaction risks require prospective clinical evaluation and actionable guidance (which combinations are beneficial vs hazardous), especially for antiplatelet/anticoagulant regimens and other drugs with narrow therapeutic windows.

1. What conditions has Panax Notoginseng been studied for?

  • Cerebrovascular disease / ischemic stroke: Studied in the context of cerebral ischemia/reperfusion (CI/R) injury (a model relevant to ischemic stroke), including effects on infarct size, neurologic/behavioral outcomes, and blood–brain barrier (BBB) integrity.

  • Cardiovascular diseases: Broadly described as having effects on the cardiovascular system, including anti-atherosclerotic activity; also specifically studied in acute myocardial infarction (AMI) models (e.g., LAD ligation in mice) and post-MI heart failure–relevant mechanisms.

  • Platelet function / thrombosis-related contexts: Panax notoginseng saponins (PNS) and constituents (e.g., Rg1, Rd) were tested for inhibition of platelet aggregation using VerifyNow Aspirin and P2Y12 assays in healthy subjects (ex vivo).

  • Inflammation and immune-related conditions: Traditional and pharmacology-focused reviews describe anti-inflammatory and immune effects; a purified polysaccharide (PNPB1) was studied in cyclophosphamide-induced immunosuppression in mice and in immune cell assays.

  • Bleeding, trauma, swelling, pain: Ethnopharmacology reviews describe use for internal/external bleeding due to injury, trauma, swelling, and pain (traditional use; not necessarily supported by controlled clinical trials in the studies reviewed here).

  • Cancer (anti-tumor activity): Reviews list anti-tumor activity among reported pharmacological effects, and herb–drug interaction (HDI) review notes interactions with anticancer agents (often framed as synergy and resistance/side-effect mitigation).

  • Drug resistance / combination therapy contexts: HDI review (2005–2022) summarizes interactions with anticancer, antiplatelet, and antimicrobial agents, including pharmacodynamic and pharmacokinetic mechanisms.

2. Does it work in treating those conditions? Summarize the evidence.

  • Ischemic stroke / CI/R injury: promising preclinical evidence.

    • Panax notoginseng–derived exosome-like nanoparticles (PDNs) entered the brain without modification and reduced infarct volume, improved behavioral outcomes, and maintained BBB integrity in a CI/R model.

    • Mechanistic findings: PDNs shifted microglia from M1 (pro-inflammatory) to M2 (anti-inflammatory) phenotype; lipids were identified as the major effective component; effects involved PI3K/Akt pathway activation.

    • Limitations: This is not human clinical evidence; it is a mechanistic/animal-model study, so clinical effectiveness and dosing are not established from these studies.

  • Acute myocardial infarction (AMI): supportive animal and ex vivo human platelet evidence.

    • In a mouse LAD-ligation AMI model, PNS reduced myocardial infarct size and improved cardiac function (as described in the study).

    • Proposed mechanisms included inducing cardiomyocyte autophagy (via phosphorylation of AMPK Thr172 and CaMKII Thr287 under glucose deprivation conditions), enhancing endothelial migration and angiogenesis, and inhibiting platelet aggregation.

    • Platelet aggregation: PNS and constituents Rg1 and Rd directly inhibited platelet aggregation in healthy subjects using VerifyNow Aspirin and P2Y12 assays, with less effect on coagulation than dual antiplatelet therapy (DAPT) in the reported comparisons.

    • Limitations: The AMI efficacy evidence is primarily animal-model based; platelet findings are ex vivo functional assays rather than clinical outcomes (e.g., fewer heart attacks or strokes).

  • Cardiovascular disease more broadly: evidence summarized in reviews; some clinical trial activity is noted but not detailed.

    • A review focused on PNS reports “increasing evidence” for effects against various cardiovascular diseases and notes four clinical trials completed and/or underway, but the studies reviewed here do not include trial outcomes, endpoints, or effect sizes.

    • Limitations: Without trial results in the studies, effectiveness in humans for specific cardiovascular indications cannot be confirmed here.

  • Immunosuppression / immune enhancement: preclinical evidence for a specific polysaccharide fraction.

    • A novel notoginseng polysaccharide (PNPB1) improved outcomes in cyclophosphamide-immunosuppressed mice: increased body weight, improved thymus and spleen indices, increased white blood cells, enhanced splenic lymphocyte proliferation, increased NO and cytokines (TNF-α, IL-2, IL-10, IFN-γ), and increased macrophage phagocytosis and TLR2 expression.

    • Limitations: These are animal and cell-based findings for an isolated polysaccharide; they do not establish clinical benefit for infections, vaccine response, or immune disorders in humans.

  • Bleeding/trauma/pain and anti-tumor claims: largely review-level and traditional-use statements in these studies.

    • Ethnopharmacology reviews describe use for bleeding and trauma and list anti-inflammatory, haemostatic, and anti-tumor activities, but the studies reviewed here do not supply controlled clinical efficacy data for these endpoints.

3. What health benefits does it have?

  • Potential cerebrovascular protection (preclinical)

    • In CI/R models, PDNs reduced infarct volume, improved behavior outcomes, and supported BBB integrity; microglial polarization toward M2 and PI3K/Akt activation were implicated.

    • A comparative review states notoginseng shows a superior protective effect on cerebrovascular disease relative to Panax ginseng (as summarized by the authors of that review).

  • Cardioprotection and vascular support (mostly preclinical/mechanistic)

    • PNS improved infarct size and cardiac function in an AMI mouse model; mechanisms included autophagy signaling (AMPK/CaMKII), endothelial migration, and angiogenesis.

    • Reviews describe anti-atherosclerotic activity and multi-pathway cardiovascular effects of PNS, and note ongoing/completed clinical trials (without outcomes provided in the studies).

  • Antiplatelet activity (ex vivo evidence)

    • PNS and constituents (Rg1, Rd) inhibited platelet aggregation in assays used clinically to assess aspirin and P2Y12-pathway effects (VerifyNow Aspirin and P2Y12).

  • Immunomodulatory / immunoenhancing effects (preclinical)

    • Notoginseng polysaccharide PNPB1 enhanced immune cell proliferation and cytokine production and improved immune organ indices and WBC counts in immunosuppressed mice.

  • Anti-inflammatory and other broad pharmacological activities (review-level)

    • Reviews list anti-inflammatory, haemostatic, and anti-tumor activities, and describe a large phytochemical diversity (>200 compounds including saponins, flavonoids, cyclopeptides).

    • Chemical composition comparisons suggest notoginseng contains relatively more saponins, volatile oil, and polyacetylenes than Panax ginseng, which may relate to differing pharmacology (hypothesis-generating rather than definitive).

4. Does it have any downsides or side effects?

  • Potential for clinically relevant herb–drug interactions (HDIs)

    • A dedicated HDI review (2005–2022) concludes Panax notoginseng can alter pharmacokinetics (absorption, distribution, metabolism, excretion) of other drugs by regulating cytochrome P450 enzymes and P-glycoprotein.

    • This is highlighted as a red flag for drugs with a narrow therapeutic window (i.e., small changes in drug exposure could cause toxicity or loss of efficacy).

  • Bleeding/clotting considerations are plausible but not fully resolved in these studies

    • Traditional use includes “stop bleeding,” yet mechanistic work also reports antiplatelet aggregation effects of PNS and constituents (Rg1, Rd). This combination suggests that effects on hemostasis may be context-dependent (e.g., different constituents, doses, preparations, or clinical settings).

    • The AMI study notes antiplatelet effects with “less affecting on coagulation compared with DAPT,” but this does not rule out bleeding risk in real-world use, especially when combined with antiplatelet/anticoagulant drugs.

  • Toxicology not detailed in the studies reviewed here

    • One review states it covers toxicology, but specific adverse events, contraindications, or incidence rates are not provided in the text shown. Therefore, side-effect frequency and severity cannot be concluded from these studies alone.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report specific pharmacogenomic findings (e.g., outcomes stratified by CYP2C19, CYP2D6, CYP3A5, ABCB1/P-gp genotypes, or other variants).

  • What can be inferred cautiously (not proven here): Because the HDI review states Panax notoginseng can regulate CYP450 enzymes and P-glycoprotein, genetic variants in these pathways could plausibly modify interaction risk or magnitude (for example, variants affecting baseline enzyme/transporter activity). However, this is a mechanistic plausibility statement, not direct evidence from the studies.

  • Practical implication: In people taking drugs strongly influenced by CYPs or P-gp—especially narrow-therapeutic-index drugs—genotype-guided dosing could theoretically be further complicated by Panax notoginseng use, but dedicated clinical pharmacogenomic studies would be needed to confirm this.

References

  1. Chemical constituents of Panax ginseng and Panax notoginseng explain why they differ in therapeutic efficacy.
    Hanbing Liu, Xiaoyan Lu, Yang Hu, Xiaohui Fan (2020) - Pharmacological research
  2. Traditional uses, botany, phytochemistry, pharmacology and toxicology of Panax notoginseng (Burk.) F.H. Chen: A review.
    Ting Wang, Rixin Guo, Guohong Zhou, Xidan Zhou, Zhenzhen Kou, Feng Sui, Chun Li, Liying Tang, Zhuju Wang (2016) - Journal of ethnopharmacology
  3. Panax notoginseng: derived exosome-like nanoparticles attenuate ischemia reperfusion injury via altering microglia polarization.
    Shiyi Li, Ru Zhang, Anni Wang, Yang Li, Miaomiao Zhang, Jisu Kim, Ying Zhu, Qizheng Wang, Yue Zhang, Ying Wei, Jianxin Wang (2023) - Journal of nanobiotechnology
  4. Herb-drug interactions between Panax notoginseng or its biologically active compounds and therapeutic drugs: A comprehensive pharmacodynamic and pharmacokinetic review.
    Yujuan Xie, Changhong Wang (2023) - Journal of ethnopharmacology
  5. Pharmacological properties, molecular mechanisms and therapeutic potential of ginsenoside Rg3 as an antioxidant and anti-inflammatory agent.
    Jing Wang, Li Zeng, Ying Zhang, Wenxiu Qi, Ziyuan Wang, Lin Tian, Daqing Zhao, Qibiao Wu, Xiangyan Li, Tan Wang (2022) - Frontiers in pharmacology
  6. Cardioprotection of Panax Notoginseng saponins against acute myocardial infarction and heart failure through inducing autophagy.
    Dandan Wang, Linyan Lv, Yue Xu, Kai Jiang, Feng Chen, Jie Qian, Ming Chen, Guanping Liu, Yaozu Xiang (2021) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  7. Panax notoginseng: Pharmacological Aspects and Toxicological Issues.
    Cesare Mancuso (2024) - Nutrients
  8. Structural characterization and immunomodulatory activity of a novel polysaccharide fromPanax notoginseng
    Xue-Lian Jiang, Gai-Fan Ma, Bin-Bin Zhao, Yan Meng, Lin-Lin Chen (2023)
  9. Panax notoginseng Saponins for Treating Coronary Artery Disease: A Functional and Mechanistic Overview.
    Lian Duan, Xingjiang Xiong, Junyuan Hu, Yongmei Liu, Jun Li, Jie Wang (2017) - Frontiers in pharmacology
  10. Saponins of Panax notoginseng: chemistry, cellular targets and therapeutic opportunities in cardiovascular diseases.
    Jingjing Liu, Yitao Wang, Lan Qiu, Yuanyuan Yu, Chunming Wang (2014) - Expert opinion on investigational drugs
  11. Panax notoginseng-microbiota interactions: From plant cultivation to medicinal application.
    Yu Xu, Mengjie Zhu, Yibin Feng, Hongxi Xu (2023) - Phytomedicine : international journal of phytotherapy and phytopharmacology
  12. Multi-layered effects of Panax notoginseng on immune system.
    Chunhao Yang, Liping Qu, Rui Wang, Feifei Wang, Zhaoxiang Yang, Fengkun Xiao (2024) - Pharmacological research
  13. Screening and verification of hemostatic effective components group of Panax Notoginseng based on spectrum-effect relationships.
    JinFeng Liu, Ge Zhang, YuQing Wang, ZhuangZhuang Hao, JingWen Xue, YiFan Lu, WenXin Fan, ChunGuo Wang, JinLi Shi (2024) - Journal of ethnopharmacology
  14. Panax notoginseng: panoramagram of phytochemical and pharmacological properties, biosynthesis, and regulation and production of ginsenosides
    Guangfei Wei, Guozhuang Zhang, Mengzhi Li, Yuqing Zheng, Wenke Zheng (2024)
  15. Pharmacokinetics and Biological Activities of Notoginsenoside R1: A Systematical Review
    Chao Wen, Xiaofei Liao, Xinyun Ye, Wentao Lai (2025)
  16. Protective Effect of Panax Notoginseng Saponins on Apolipoprotein-E-deficient Atherosclerosis-prone Mice.
    He Yang, Zuodong Liu, Xiangka Hu, Xiaojuan Liu, Liuming Gui, Zengxiaorui Cai, Chunmei Dai (2022) - Current pharmaceutical design
  17. The Antiviral Effect of Panax Notoginseng Polysaccharides by Inhibiting PRV Adsorption and Replication In Vitro.
    Changchao Huan, Ziyan Zhou, Jingting Yao, Bo Ni, Song Gao (2022) - Molecules (Basel, Switzerland)
  18. Panax notoginseng for Inflammation-Related Chronic Diseases: A Review on the Modulations of Multiple Pathways.
    Yu Xu, Hor-Yue Tan, Sha Li, Ning Wang, Yibin Feng (2018) - The American journal of Chinese medicine
  19. Rhizospheric fungi of Panax notoginseng: diversity and antagonism to host phytopathogens.
    Cui-Ping Miao, Qi-Li Mi, Xin-Guo Qiao, You-Kun Zheng, You-Wei Chen, Li-Hua Xu, Hui-Lin Guan, Li-Xing Zhao (2016) - Journal of ginseng research


Related

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!